Loading…
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints
Classical Hodgkin lymphoma is curable in the majority of cases with chemotherapy and/or radiation. However, 15-20% of patients ultimately relapse and succumb to their disease. Pathologically, classical Hodgkin lymphoma is characterized by rare tumor-initiating Reed-Sternberg cells surrounded by a de...
Saved in:
| Published in: | Haematologica (Roma) 2016-07, Vol.101 (7), p.794-802 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c474t-ed71efaa3ed7683b53b469fa381a97fff65271f1141331bb97c9f8f465637df43 |
|---|---|
| cites | |
| container_end_page | 802 |
| container_issue | 7 |
| container_start_page | 794 |
| container_title | Haematologica (Roma) |
| container_volume | 101 |
| creator | Vardhana, Santosha Younes, Anas |
| description | Classical Hodgkin lymphoma is curable in the majority of cases with chemotherapy and/or radiation. However, 15-20% of patients ultimately relapse and succumb to their disease. Pathologically, classical Hodgkin lymphoma is characterized by rare tumor-initiating Reed-Sternberg cells surrounded by a dense immune microenvironment. However, the role of the immune microenvironment, particularly T and B cells, in either promoting or restricting Classical Hodgkin lymphoma growth remains undefined. Recent dramatic clinical responses seen using monoclonal antibodies against PD-1, a cell surface receptor whose primary function is to restrict T cell activation, have reignited questions regarding the function of the adaptive immune system in classical Hodgkin lymphoma. This review summarizes what is known regarding T cells, B cells, and immune checkpoints in classical Hodgkin lymphoma. |
| doi_str_mv | 10.3324/haematol.2015.132761 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d69cdc9af66f48fa86a2e4d6870cf573</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d69cdc9af66f48fa86a2e4d6870cf573</doaj_id><sourcerecordid>1801424628</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-ed71efaa3ed7683b53b469fa381a97fff65271f1141331bb97c9f8f465637df43</originalsourceid><addsrcrecordid>eNpVkUtvEzEURi0EoqHwDxCaJQsm-P1ggQQV0EqV2IQFK8vjR8bt2A72pFL_PRPSVHR1r-x7j63vAPAWwTUhmH4cjU9mLtMaQ8TWiGDB0TOwQkzhXgqMnoMVJAr2HAp5Bl61dgMhhkqJl-AMC8IZZWoFfm9G38WU9tl3KdpafL6LteTk89zF3F0Wt71d6nSfdmNJ5lO36ayfpvah-3pqTHYnhB29vd2VmOf2GrwIZmr-zUM9B7--f9tcXPbXP39cXXy57i0VdO69E8gHY8jScEkGRgbKVTBEIqNECIEzLFBAiCJC0DAoYVWQgXLGiXCBknNwdeS6Ym70rsZk6r0uJup_B6VutalztJPXjivrrDKB80BlMJIb7KnjUkAbmCAL6_ORtdsPyTu7hFDN9AT69CbHUW_LnWYQUsrkAnj_AKjlz963WafYDjGZ7Mu-aSQhophyfBilx9El9NaqD4_PIKgPhvXJsD4Y1kfDy9q7_7_4uHRSSv4CZrqlkg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1801424628</pqid></control><display><type>article</type><title>The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints</title><source>Freely Accessible Science Journals - check A-Z of ejournals</source><source>PubMed Central</source><creator>Vardhana, Santosha ; Younes, Anas</creator><creatorcontrib>Vardhana, Santosha ; Younes, Anas</creatorcontrib><description>Classical Hodgkin lymphoma is curable in the majority of cases with chemotherapy and/or radiation. However, 15-20% of patients ultimately relapse and succumb to their disease. Pathologically, classical Hodgkin lymphoma is characterized by rare tumor-initiating Reed-Sternberg cells surrounded by a dense immune microenvironment. However, the role of the immune microenvironment, particularly T and B cells, in either promoting or restricting Classical Hodgkin lymphoma growth remains undefined. Recent dramatic clinical responses seen using monoclonal antibodies against PD-1, a cell surface receptor whose primary function is to restrict T cell activation, have reignited questions regarding the function of the adaptive immune system in classical Hodgkin lymphoma. This review summarizes what is known regarding T cells, B cells, and immune checkpoints in classical Hodgkin lymphoma.</description><identifier>ISSN: 0390-6078</identifier><identifier>EISSN: 1592-8721</identifier><identifier>DOI: 10.3324/haematol.2015.132761</identifier><identifier>PMID: 27365459</identifier><language>eng</language><publisher>Italy: Ferrata Storti Foundation</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; B-Lymphocytes - drug effects ; B-Lymphocytes - immunology ; B-Lymphocytes - metabolism ; Biomarkers ; Combined Modality Therapy ; Hodgkin Disease - drug therapy ; Hodgkin Disease - immunology ; Hodgkin Disease - metabolism ; Hodgkin Disease - pathology ; Humans ; Immunomodulation - drug effects ; Immunotherapy ; Molecular Targeted Therapy ; Review ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology ; T-Lymphocytes - metabolism ; Tumor Microenvironment - drug effects ; Tumor Microenvironment - immunology</subject><ispartof>Haematologica (Roma), 2016-07, Vol.101 (7), p.794-802</ispartof><rights>Copyright© Ferrata Storti Foundation.</rights><rights>Copyright© Ferrata Storti Foundation 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-ed71efaa3ed7683b53b469fa381a97fff65271f1141331bb97c9f8f465637df43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004458/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004458/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27365459$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vardhana, Santosha</creatorcontrib><creatorcontrib>Younes, Anas</creatorcontrib><title>The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints</title><title>Haematologica (Roma)</title><addtitle>Haematologica</addtitle><description>Classical Hodgkin lymphoma is curable in the majority of cases with chemotherapy and/or radiation. However, 15-20% of patients ultimately relapse and succumb to their disease. Pathologically, classical Hodgkin lymphoma is characterized by rare tumor-initiating Reed-Sternberg cells surrounded by a dense immune microenvironment. However, the role of the immune microenvironment, particularly T and B cells, in either promoting or restricting Classical Hodgkin lymphoma growth remains undefined. Recent dramatic clinical responses seen using monoclonal antibodies against PD-1, a cell surface receptor whose primary function is to restrict T cell activation, have reignited questions regarding the function of the adaptive immune system in classical Hodgkin lymphoma. This review summarizes what is known regarding T cells, B cells, and immune checkpoints in classical Hodgkin lymphoma.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>B-Lymphocytes - drug effects</subject><subject>B-Lymphocytes - immunology</subject><subject>B-Lymphocytes - metabolism</subject><subject>Biomarkers</subject><subject>Combined Modality Therapy</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin Disease - immunology</subject><subject>Hodgkin Disease - metabolism</subject><subject>Hodgkin Disease - pathology</subject><subject>Humans</subject><subject>Immunomodulation - drug effects</subject><subject>Immunotherapy</subject><subject>Molecular Targeted Therapy</subject><subject>Review</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><subject>T-Lymphocytes - metabolism</subject><subject>Tumor Microenvironment - drug effects</subject><subject>Tumor Microenvironment - immunology</subject><issn>0390-6078</issn><issn>1592-8721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUtvEzEURi0EoqHwDxCaJQsm-P1ggQQV0EqV2IQFK8vjR8bt2A72pFL_PRPSVHR1r-x7j63vAPAWwTUhmH4cjU9mLtMaQ8TWiGDB0TOwQkzhXgqMnoMVJAr2HAp5Bl61dgMhhkqJl-AMC8IZZWoFfm9G38WU9tl3KdpafL6LteTk89zF3F0Wt71d6nSfdmNJ5lO36ayfpvah-3pqTHYnhB29vd2VmOf2GrwIZmr-zUM9B7--f9tcXPbXP39cXXy57i0VdO69E8gHY8jScEkGRgbKVTBEIqNECIEzLFBAiCJC0DAoYVWQgXLGiXCBknNwdeS6Ym70rsZk6r0uJup_B6VutalztJPXjivrrDKB80BlMJIb7KnjUkAbmCAL6_ORtdsPyTu7hFDN9AT69CbHUW_LnWYQUsrkAnj_AKjlz963WafYDjGZ7Mu-aSQhophyfBilx9El9NaqD4_PIKgPhvXJsD4Y1kfDy9q7_7_4uHRSSv4CZrqlkg</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Vardhana, Santosha</creator><creator>Younes, Anas</creator><general>Ferrata Storti Foundation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20160701</creationdate><title>The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints</title><author>Vardhana, Santosha ; Younes, Anas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-ed71efaa3ed7683b53b469fa381a97fff65271f1141331bb97c9f8f465637df43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>B-Lymphocytes - drug effects</topic><topic>B-Lymphocytes - immunology</topic><topic>B-Lymphocytes - metabolism</topic><topic>Biomarkers</topic><topic>Combined Modality Therapy</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin Disease - immunology</topic><topic>Hodgkin Disease - metabolism</topic><topic>Hodgkin Disease - pathology</topic><topic>Humans</topic><topic>Immunomodulation - drug effects</topic><topic>Immunotherapy</topic><topic>Molecular Targeted Therapy</topic><topic>Review</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><topic>T-Lymphocytes - metabolism</topic><topic>Tumor Microenvironment - drug effects</topic><topic>Tumor Microenvironment - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vardhana, Santosha</creatorcontrib><creatorcontrib>Younes, Anas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Haematologica (Roma)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vardhana, Santosha</au><au>Younes, Anas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints</atitle><jtitle>Haematologica (Roma)</jtitle><addtitle>Haematologica</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>101</volume><issue>7</issue><spage>794</spage><epage>802</epage><pages>794-802</pages><issn>0390-6078</issn><eissn>1592-8721</eissn><abstract>Classical Hodgkin lymphoma is curable in the majority of cases with chemotherapy and/or radiation. However, 15-20% of patients ultimately relapse and succumb to their disease. Pathologically, classical Hodgkin lymphoma is characterized by rare tumor-initiating Reed-Sternberg cells surrounded by a dense immune microenvironment. However, the role of the immune microenvironment, particularly T and B cells, in either promoting or restricting Classical Hodgkin lymphoma growth remains undefined. Recent dramatic clinical responses seen using monoclonal antibodies against PD-1, a cell surface receptor whose primary function is to restrict T cell activation, have reignited questions regarding the function of the adaptive immune system in classical Hodgkin lymphoma. This review summarizes what is known regarding T cells, B cells, and immune checkpoints in classical Hodgkin lymphoma.</abstract><cop>Italy</cop><pub>Ferrata Storti Foundation</pub><pmid>27365459</pmid><doi>10.3324/haematol.2015.132761</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0390-6078 |
| ispartof | Haematologica (Roma), 2016-07, Vol.101 (7), p.794-802 |
| issn | 0390-6078 1592-8721 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_d69cdc9af66f48fa86a2e4d6870cf573 |
| source | Freely Accessible Science Journals - check A-Z of ejournals; PubMed Central |
| subjects | Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use B-Lymphocytes - drug effects B-Lymphocytes - immunology B-Lymphocytes - metabolism Biomarkers Combined Modality Therapy Hodgkin Disease - drug therapy Hodgkin Disease - immunology Hodgkin Disease - metabolism Hodgkin Disease - pathology Humans Immunomodulation - drug effects Immunotherapy Molecular Targeted Therapy Review T-Lymphocytes - drug effects T-Lymphocytes - immunology T-Lymphocytes - metabolism Tumor Microenvironment - drug effects Tumor Microenvironment - immunology |
| title | The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T19%3A05%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20immune%20microenvironment%20in%20Hodgkin%20lymphoma:%20T%20cells,%20B%20cells,%20and%20immune%20checkpoints&rft.jtitle=Haematologica%20(Roma)&rft.au=Vardhana,%20Santosha&rft.date=2016-07-01&rft.volume=101&rft.issue=7&rft.spage=794&rft.epage=802&rft.pages=794-802&rft.issn=0390-6078&rft.eissn=1592-8721&rft_id=info:doi/10.3324/haematol.2015.132761&rft_dat=%3Cproquest_doaj_%3E1801424628%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-ed71efaa3ed7683b53b469fa381a97fff65271f1141331bb97c9f8f465637df43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1801424628&rft_id=info:pmid/27365459&rfr_iscdi=true |